Institut Necker Enfants Malades; Université de Paris.
Institut Necker Enfants Malades; Université de Paris; Centre de Référence Maladies Rares Mucoviscidose et Maladies apparentées, Assistance Publique Hôpitaux de Paris;
J Vis Exp. 2022 Apr 22(182). doi: 10.3791/63409.
Human nasal epithelial (HNE) cells are easy to collect by simple, non-invasive nasal brushing. Patient-derived primary HNE cells can be amplified and differentiated into a pseudo-stratified epithelium in air-liquid interface conditions to quantify cyclic AMP-mediated Chloride (Cl) transport as an index of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) function. If critical steps such as quality of nasal brushing and cell density upon cryopreservation are performed efficiently, HNE cells can be successfully biobanked. Moreover, short-circuit current studies demonstrate that freeze-thawing does not significantly modify HNE cells' electrophysiological properties and response to CFTR modulators. In the culture conditions used in this study, when less than 2 x 10 cells are frozen per cryovial, the failure rate is very high. We recommend freezing at least 3 x 10 cells per cryovial. We show that dual therapies combining a CFTR corrector with a CFTR potentiator have a comparable correction efficacy for CFTR activity in F508del-homozygous HNE cells. Triple therapy VX-445 + VX-661 + VX-770 significantly increased correction of CFTR activity compared to dual therapy VX-809 + VX-770. The measure of CFTR activity in HNE cells is a promising pre-clinical biomarker useful to guide CFTR modulator therapy.
人鼻腔上皮(HNE)细胞易于通过简单、非侵入性的鼻腔刷洗收集。患者来源的原代 HNE 细胞可在气液界面条件下扩增和分化为假复层上皮,以定量环磷酸腺苷介导的氯(Cl)转运作为囊性纤维化跨膜电导调节剂(CFTR)功能的指标。如果能够有效地完成关键步骤,如鼻腔刷洗的质量和冷冻保存时的细胞密度,那么 HNE 细胞就可以成功地被生物银行存储。此外,短路电流研究表明,冻融不会显著改变 HNE 细胞的电生理特性及其对 CFTR 调节剂的反应。在本研究中使用的培养条件下,如果每个冷冻管中冷冻的细胞数少于 2 x 10 个,那么失败率非常高。我们建议每个冷冻管中至少冷冻 3 x 10 个细胞。我们表明,联合使用 CFTR 校正剂和 CFTR 增强剂的双重疗法对 F508del-纯合子 HNE 细胞中 CFTR 活性具有相当的校正效果。与双疗法 VX-809 + VX-770 相比,VX-445 + VX-661 + VX-770 的三联疗法显著增加了 CFTR 活性的校正。HNE 细胞中 CFTR 活性的测量是一种很有前途的临床前生物标志物,可用于指导 CFTR 调节剂治疗。